Teva Pharma (TEVA) PT Raised to $22 at RBC Capital
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $37.34 +1.44%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
RBC Capital analyst Randall Stanicky raised the price target on Teva Pharma (NYSE: TEVA) to $22.00 (from $19.00) while maintaining a Sector Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Flux Power Holdings (FLUX) PT Lowered to $1.60 at Roth/MKM
- Bill.com Holdings Inc. (BILL) PT Raised to $59 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
